Características clínicas del cáncer de mama triple negativo en una institución de cuarto nivel de Barranquilla 2021-2022

Introducción: El TNBC se caracteriza por la ausencia de receptores hormonales estrogénicos y progesterona; así como, del receptor 2 del factor de crecimiento epidérmico humano (HER2). Los TNBC se asocian con altas tasas de recurrencia, metástasis rápidas, supervivencia deficiente y mayor mortalidad...

Full description

Autores:
Mestre Sequeda, Epitafio Rafael
Morales Díaz, Esteban Andrés
Tipo de recurso:
Fecha de publicación:
2023
Institución:
Universidad Libre
Repositorio:
RIU - Repositorio Institucional UniLibre
Idioma:
OAI Identifier:
oai:repository.unilibre.edu.co:10901/28475
Acceso en línea:
https://hdl.handle.net/10901/28475
Palabra clave:
Cáncer de mama triple negativo
Cáncer de mama
Factores de riesgo
Epidemiología
Triple negative breast cancer
Breast cancer
Risk factors
Epidemiology
Cáncer
Neoplasias de la mama - Epidemiología
Factores de riesgo
Rights
License
http://purl.org/coar/access_right/c_abf2
id RULIBRE2_0f69de6e65676b8b9d30b8864cf66bac
oai_identifier_str oai:repository.unilibre.edu.co:10901/28475
network_acronym_str RULIBRE2
network_name_str RIU - Repositorio Institucional UniLibre
repository_id_str
dc.title.spa.fl_str_mv Características clínicas del cáncer de mama triple negativo en una institución de cuarto nivel de Barranquilla 2021-2022
title Características clínicas del cáncer de mama triple negativo en una institución de cuarto nivel de Barranquilla 2021-2022
spellingShingle Características clínicas del cáncer de mama triple negativo en una institución de cuarto nivel de Barranquilla 2021-2022
Cáncer de mama triple negativo
Cáncer de mama
Factores de riesgo
Epidemiología
Triple negative breast cancer
Breast cancer
Risk factors
Epidemiology
Cáncer
Neoplasias de la mama - Epidemiología
Factores de riesgo
title_short Características clínicas del cáncer de mama triple negativo en una institución de cuarto nivel de Barranquilla 2021-2022
title_full Características clínicas del cáncer de mama triple negativo en una institución de cuarto nivel de Barranquilla 2021-2022
title_fullStr Características clínicas del cáncer de mama triple negativo en una institución de cuarto nivel de Barranquilla 2021-2022
title_full_unstemmed Características clínicas del cáncer de mama triple negativo en una institución de cuarto nivel de Barranquilla 2021-2022
title_sort Características clínicas del cáncer de mama triple negativo en una institución de cuarto nivel de Barranquilla 2021-2022
dc.creator.fl_str_mv Mestre Sequeda, Epitafio Rafael
Morales Díaz, Esteban Andrés
dc.contributor.advisor.none.fl_str_mv Hernández Lastra, Ángel
Varela Prieto, Lourdes
dc.contributor.author.none.fl_str_mv Mestre Sequeda, Epitafio Rafael
Morales Díaz, Esteban Andrés
dc.subject.spa.fl_str_mv Cáncer de mama triple negativo
Cáncer de mama
Factores de riesgo
Epidemiología
topic Cáncer de mama triple negativo
Cáncer de mama
Factores de riesgo
Epidemiología
Triple negative breast cancer
Breast cancer
Risk factors
Epidemiology
Cáncer
Neoplasias de la mama - Epidemiología
Factores de riesgo
dc.subject.subjectenglish.spa.fl_str_mv Triple negative breast cancer
Breast cancer
Risk factors
Epidemiology
dc.subject.lemb.spa.fl_str_mv Cáncer
Neoplasias de la mama - Epidemiología
Factores de riesgo
description Introducción: El TNBC se caracteriza por la ausencia de receptores hormonales estrogénicos y progesterona; así como, del receptor 2 del factor de crecimiento epidérmico humano (HER2). Los TNBC se asocian con altas tasas de recurrencia, metástasis rápidas, supervivencia deficiente y mayor mortalidad en comparación con otros subtipos histológicos de cáncer de mama. El objetivo del estudio fue establecer las características clínicas del cáncer de mama triple negativo, en pacientes atendidas en la Organización Clínica Bonnadona Prevenir S.A.S. en el periodo de 2021-2022. Materiales y métodos: Estudio retrospectivo descriptivo transversal observacional, donde se evaluó la frecuencia del cáncer de mama subtipo triple negativo, Asimismo, las variables clínicas. En mujeres atendidas en la Organización Clínica Bonnadona Prevenir S.A.S. en Barranquilla, Colombia en el periodo 2021-2022. Resultados: Se estudiaron 350 pacientes, de los cuales 61 pacientes (17.4%) presentaban el inmunofenotipo triple negativo. La edad promedio fue de 54,5 años, 74% eran multíparas, 85% brindaron lactancia materna, 70% eran postmenopáusicas y el estadio clínico más frecuente fue el IIIB. Conclusión: En el presente estudio el 57.35% de la población exhibió un estadio clínico avanzado en el momento del diagnóstico; asimismo, las características clínicas son congruentes con los reportes en la literatura.
publishDate 2023
dc.date.created.none.fl_str_mv 2023
dc.date.accessioned.none.fl_str_mv 2024-02-21T19:33:16Z
dc.date.available.none.fl_str_mv 2024-02-21T19:33:16Z
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.local.spa.fl_str_mv Tesis de Especialización
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/bachelorThesis
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10901/28475
url https://hdl.handle.net/10901/28475
dc.relation.references.spa.fl_str_mv Siegel R, Miller K, Fuchs H, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33
Instituto Nacional de Cancerología (INC). Anuario estadístico 2021. Bogotá, D. C.: INC; 2022. Disponible en: www.cancer.gov.co
Almansour N. Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front Mol Biosci. 2022; 9:836417
Yin L, Duan J, Bian X, Yu S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020; 22(1):61
Chang J, Ding Y, Tahir M, Shen Y, Gao J, Chen L. A deep learning model based on sparse auto-encoder for prioritizing cancer-related genes and drug target combinations. Carcinogenesis. 2019; 40(5): 624-632
Howard F, Olopade O. Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer J. 2021; 27(1): 8-16
Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pac J Cancer Prev. 2016; 17(S3): 43-6
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio I, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncology. 2019;30 (8): 1194–220
Chaudhary L, Wilkinson K, Kong A. Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy? Surg Oncol Clin N Am. 2018; 27(1):141–53
Díaz S, Wiesner C, Perry F, Poveda C, Carvajal A, Bermúdez J, et al. Educación en Colombia para la detección temprana del cáncer de mama. Rev Colomb Cir. 2019; 34, 329-337
The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. 2012; Nature 490, 61–70
Bianchini G, Balko J, Mayer I, Sanders I, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016; 13, 674–690
Fragomeni SM, Sciallis A, Jeruss JS. Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am. 2018;27(1):95–120
Reis-Filho J, Pusztai L. Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet. 2011;378(9805):1812–1823
Gradishar W, Robert C, Anderson B, Balassanian R, Blair S, Burstein H, et al. NCCN Guidelines Version 1.2016 Breast Cancer Panel Members. Natl Compr Cancer Netw. 2016
Subik K, Lee J, Baxter L, Strzepek T, Costello D, Crowley P, et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl). 2010 May 20;4:35-41
Prat A, Cheang M, Martín M, Parker J, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013; 31(2):203–209
Vuong D, Simpson P, Green B, Cummings M, Lakhani S. Molecular classification of breast cancer. Virchows Arch. 2014; 465(1):1–14
Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, et al. Differential response of immunohistochemically defined breast cancer subtypes to anthracyclinebased adjuvant chemotherapy with or without paclitaxel. PLoS One. 2012;7(6):e37946
Joyce D, Murphy D, Lowery A, Curran C, Barry K, Malone C, et al. Prospective comparison of outcome after treatment for triple-negative and non-triple-negative breast cancer. Surgeon. 2017; 15(5): 272–7
Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted thera- pies. J Clin Invest. 2011; 121(7): 2750–67
Kim S, Moon B, Lim W, Park S, Cho M, Sung S. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers. Clin Breast Cancer. 2018; 18(5): e1123-e1132
Caparica R, Lambertini M, de Azambuja E. How I treat metastatic triple-negative breast cancer. ESMO Open. 2019; 4: e000504-e
Mahon S. Response to “Biologic, demographic, and social factors affecting triple negative breast cancer outcomes.” Clin J Oncol Nurs. 2015; 19(3):244
Picerno T, Damewood A, Sims-Mourtada J. Obesity and race as risk factors in triplenegative breast cancer. Gynecologic Oncology. 2016; 141(1): 190-190
Awan S, Malozzi C, Omar B, Poosarla T. Assessment of cardiovascular disease risk factor control in triple negative breast cancer patients. Jacc: CardioOncology. 2022; 4(1): S13-S13
Samuel S, Varghese E, Varghese S, Büsselberg D. Challenges and perspectives in the treatment of diabetes associated breast cancer. Cancer Treatment Reviews. 2018; 70, 98-111
Turner N, Reis-Filho J. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006. 25; 5846–5853
Jung J, Kang E, Gwak J, Seo A, Park S, Lee A, et al. Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients. Curr Oncol. 2016; 23(5):298-303
Woodward W. Inflammatory breast cancer: unique biological and therapeutic considerations. Lancet Oncol. 2015; 16: e568-e576
Davidson N. Cáncer de mama y trastornos benignos de la mama. Goldman-Cecil. Tratado de medicina interna, 2021. 188, 1321-1329
Sun L, Wu A, Bean G, Hagemann I, Lin Ch. Molecular Testing in Breast Cancer. Journal of Molecular Diagnostics. 2021; 23(11): 1422-1432
Franklin W, Aisner D, Davies K, Crooks K, Publicar M, Kleinschmidt-DeMasters B. Abeloff. Oncología clínica, Sexta edición. 2020; 15, 225-253
Jitariu A, Cîmpean A, Ribatti D, Raica M. Triple negative breast cancer: the kiss of death. Oncotarget. 2017; 8(28): 46652-46662
Medina M, Oza G, Sharma A, Arriaga L, Hernández J, Rotello V, et al. Triple negative breast cancer: A review of conventional and advanced therapeutic strategies. Int J Environ Res Public Health. 2020; 17(6):1–32
Berry D, Cirrincione C, Henderson I, Citron M, Budman D, Goldstein L, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006; 295(14):1658-67
Jones S, Savin M, Holmes F, O'Shaughnessy J, Blum J, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006; 24(34): 5381-7
Sikov W, Berry D, Perou C, Singh B, Cirrincione C, Tolaney S, et el. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015; 33(1): 13-21
Vaz-Luis I, Ottesen R, Hughes M, Mamet R, Burstein H, Edge S, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014; 32(20):2142-50
Tutt A, Garber J, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021; 384(25): 2394- 2405
Tung N, Zakalik D, Somerfield M. Hereditary Breast Cancer Guideline Expert Panel. Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update. J Clin Oncol. 2021; 39(26): 2959-2961
Abdel-Rahman O. Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. Breast Cancer Res Treat 2018; 168: pp. 269- 275
Ibis K, Ozkurt S, Kucucuk S, Yavuz E, Saip P. Comparison of pathological prognostic stage and anatomic stage groups according to the updated version of the American Joint Committee on Cancer (AJCC) breast cancer staging 8th edition. Med Sci Monit 2018; 24: pp. 3637-3643
Liedtke C, Mazouni C, Hess K, André F, Tordai A, Mejia J, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81
Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008; 68(9): 3108-14
Lin N, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012; 118(22): 5463-72
Mahtani R, Kittaneh M, Kalinsky K, Mamounas E, Badve S, Vogel C, et al. Advances in therapeutic approaches for triple-negative breast cancer. Clin Breast Cancer. 2021;21(5):383–90
Sung H, Wiese D, Jatoi I, Jemal A. State variation in racial and ethnic disparities in incidence of triple-negative breast cancer among US women. JAMA Oncol. 2023;9(5):700–4
Downs-Canner S, Mittendorf EA. Selecting triple negative breast cancer patients for immunotherapy. Surg Oncol Clin N Am 2023; 32-4
Yoon J, Knapp G, Quan ML, Bouchard-Fortier A. Cancer-specific outcomes in the elderly with triple-negative breast cancer: A systematic review. Curr Oncol. 2021;28(4):2337–45
Zouré AA, Bambara AH, Sawadogo AY, Ouattara AK, Ouédraogo M, Traoré SS, et al. Multiparity and breast cancer risk factor among women in Burkina Faso. Asian Pac J Cancer Prev. 2016;17(12):5095–9
Pavese F, Capoluongo ED, Muratore M, Minucci A, Santonocito C, Fuso P, et al. BRCA mutation status in triple-negative breast cancer patients treated with Neoadjuvant chemotherapy: A pivotal role for treatment decision-making. Cancers (Basel). 2022;14(19):4571
Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020;10(1):225
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72
Brawley OW, Lansey DG. Disparities in breast cancer outcomes and how to resolve them. Hematol Oncol Clin North Am. 2023;37(1):1–15
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv http://purl.org/coar/access_right/c_abf2
dc.format.spa.fl_str_mv PDF
dc.coverage.spatial.spa.fl_str_mv Barranquilla
institution Universidad Libre
bitstream.url.fl_str_mv http://repository.unilibre.edu.co/bitstream/10901/28475/5/MESTRE.pdf.jpg
http://repository.unilibre.edu.co/bitstream/10901/28475/6/FORMULARIO%20AUTORIZACION.pdf.jpg
http://repository.unilibre.edu.co/bitstream/10901/28475/3/license.txt
http://repository.unilibre.edu.co/bitstream/10901/28475/1/MESTRE.pdf
http://repository.unilibre.edu.co/bitstream/10901/28475/2/FORMULARIO%20AUTORIZACION.pdf
bitstream.checksum.fl_str_mv 640da69712fdc788568d4cbda03807f5
f887b39f7c8d5f8f7424ff06e41f668b
8a4605be74aa9ea9d79846c1fba20a33
673af96ac6e52f6c0605ea69e4d9217a
60285f140c8ae9d010df68c37bbc1f48
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Unilibre
repository.mail.fl_str_mv repositorio@unilibrebog.edu.co
_version_ 1814090580524793856
spelling Hernández Lastra, ÁngelVarela Prieto, LourdesMestre Sequeda, Epitafio RafaelMorales Díaz, Esteban AndrésBarranquilla2024-02-21T19:33:16Z2024-02-21T19:33:16Z2023https://hdl.handle.net/10901/28475Introducción: El TNBC se caracteriza por la ausencia de receptores hormonales estrogénicos y progesterona; así como, del receptor 2 del factor de crecimiento epidérmico humano (HER2). Los TNBC se asocian con altas tasas de recurrencia, metástasis rápidas, supervivencia deficiente y mayor mortalidad en comparación con otros subtipos histológicos de cáncer de mama. El objetivo del estudio fue establecer las características clínicas del cáncer de mama triple negativo, en pacientes atendidas en la Organización Clínica Bonnadona Prevenir S.A.S. en el periodo de 2021-2022. Materiales y métodos: Estudio retrospectivo descriptivo transversal observacional, donde se evaluó la frecuencia del cáncer de mama subtipo triple negativo, Asimismo, las variables clínicas. En mujeres atendidas en la Organización Clínica Bonnadona Prevenir S.A.S. en Barranquilla, Colombia en el periodo 2021-2022. Resultados: Se estudiaron 350 pacientes, de los cuales 61 pacientes (17.4%) presentaban el inmunofenotipo triple negativo. La edad promedio fue de 54,5 años, 74% eran multíparas, 85% brindaron lactancia materna, 70% eran postmenopáusicas y el estadio clínico más frecuente fue el IIIB. Conclusión: En el presente estudio el 57.35% de la población exhibió un estadio clínico avanzado en el momento del diagnóstico; asimismo, las características clínicas son congruentes con los reportes en la literatura.Universidad Libre Seccional Barranquilla -- Facultad de Ciencias de la Salud -- Especialización en Medicina InternaIntroduction: TNBC is characterized by the absence of estrogen and progesterone hormone receptors; as well as human epidermal growth factor receptor 2 (HER2). TNBC is associated with an increased rate of recurrence, distant metastasis, poor survival, and higher mortality compared with other pathological subtypes of breast cancer. The objective of the study was to establish the clinical characteristics of triple negative breast cancer in patients treated at the Organization Clínica Bonnadona Prevenir S.A.S. in the period of 2021-2022. Methodology: A retrospective descriptive cross-sectional observational study, where the frequency of triple negative subtype breast cancer was evaluated, as well as clinical variables and gynecologic and obstetric history, women treated at the Organización Clínica Bonnadona Prevenir S.A.S. in Barranquilla, Colombia in the period 2021-2022. Results: 350 patients were studied, of which 61 patients (17.4%) presented the triple negative immunophenotype. The average age was 54 years, 74% were multiparous, 85% breastfed, 70% were menopausal, the most frequent clinical stage was IIIB. Conclusion: In this study, 57.35% of the population exhibited an advanced clinical stage at the time of diagnosis; Likewise, the clinical characteristics are consistent with the reports in the literature.PDFCáncer de mama triple negativoCáncer de mamaFactores de riesgoEpidemiologíaTriple negative breast cancerBreast cancerRisk factorsEpidemiologyCáncerNeoplasias de la mama - EpidemiologíaFactores de riesgoCaracterísticas clínicas del cáncer de mama triple negativo en una institución de cuarto nivel de Barranquilla 2021-2022Tesis de Especializacióninfo:eu-repo/semantics/bachelorThesishttp://purl.org/coar/resource_type/c_7a1fSiegel R, Miller K, Fuchs H, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33Instituto Nacional de Cancerología (INC). Anuario estadístico 2021. Bogotá, D. C.: INC; 2022. Disponible en: www.cancer.gov.coAlmansour N. Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front Mol Biosci. 2022; 9:836417Yin L, Duan J, Bian X, Yu S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020; 22(1):61Chang J, Ding Y, Tahir M, Shen Y, Gao J, Chen L. A deep learning model based on sparse auto-encoder for prioritizing cancer-related genes and drug target combinations. Carcinogenesis. 2019; 40(5): 624-632Howard F, Olopade O. Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer J. 2021; 27(1): 8-16Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pac J Cancer Prev. 2016; 17(S3): 43-6Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio I, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncology. 2019;30 (8): 1194–220Chaudhary L, Wilkinson K, Kong A. Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy? Surg Oncol Clin N Am. 2018; 27(1):141–53Díaz S, Wiesner C, Perry F, Poveda C, Carvajal A, Bermúdez J, et al. Educación en Colombia para la detección temprana del cáncer de mama. Rev Colomb Cir. 2019; 34, 329-337The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. 2012; Nature 490, 61–70Bianchini G, Balko J, Mayer I, Sanders I, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016; 13, 674–690Fragomeni SM, Sciallis A, Jeruss JS. Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am. 2018;27(1):95–120Reis-Filho J, Pusztai L. Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet. 2011;378(9805):1812–1823Gradishar W, Robert C, Anderson B, Balassanian R, Blair S, Burstein H, et al. NCCN Guidelines Version 1.2016 Breast Cancer Panel Members. Natl Compr Cancer Netw. 2016Subik K, Lee J, Baxter L, Strzepek T, Costello D, Crowley P, et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl). 2010 May 20;4:35-41Prat A, Cheang M, Martín M, Parker J, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013; 31(2):203–209Vuong D, Simpson P, Green B, Cummings M, Lakhani S. Molecular classification of breast cancer. Virchows Arch. 2014; 465(1):1–14Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, et al. Differential response of immunohistochemically defined breast cancer subtypes to anthracyclinebased adjuvant chemotherapy with or without paclitaxel. PLoS One. 2012;7(6):e37946Joyce D, Murphy D, Lowery A, Curran C, Barry K, Malone C, et al. Prospective comparison of outcome after treatment for triple-negative and non-triple-negative breast cancer. Surgeon. 2017; 15(5): 272–7Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted thera- pies. J Clin Invest. 2011; 121(7): 2750–67Kim S, Moon B, Lim W, Park S, Cho M, Sung S. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers. Clin Breast Cancer. 2018; 18(5): e1123-e1132Caparica R, Lambertini M, de Azambuja E. How I treat metastatic triple-negative breast cancer. ESMO Open. 2019; 4: e000504-eMahon S. Response to “Biologic, demographic, and social factors affecting triple negative breast cancer outcomes.” Clin J Oncol Nurs. 2015; 19(3):244Picerno T, Damewood A, Sims-Mourtada J. Obesity and race as risk factors in triplenegative breast cancer. Gynecologic Oncology. 2016; 141(1): 190-190Awan S, Malozzi C, Omar B, Poosarla T. Assessment of cardiovascular disease risk factor control in triple negative breast cancer patients. Jacc: CardioOncology. 2022; 4(1): S13-S13Samuel S, Varghese E, Varghese S, Büsselberg D. Challenges and perspectives in the treatment of diabetes associated breast cancer. Cancer Treatment Reviews. 2018; 70, 98-111Turner N, Reis-Filho J. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006. 25; 5846–5853Jung J, Kang E, Gwak J, Seo A, Park S, Lee A, et al. Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients. Curr Oncol. 2016; 23(5):298-303Woodward W. Inflammatory breast cancer: unique biological and therapeutic considerations. Lancet Oncol. 2015; 16: e568-e576Davidson N. Cáncer de mama y trastornos benignos de la mama. Goldman-Cecil. Tratado de medicina interna, 2021. 188, 1321-1329Sun L, Wu A, Bean G, Hagemann I, Lin Ch. Molecular Testing in Breast Cancer. Journal of Molecular Diagnostics. 2021; 23(11): 1422-1432Franklin W, Aisner D, Davies K, Crooks K, Publicar M, Kleinschmidt-DeMasters B. Abeloff. Oncología clínica, Sexta edición. 2020; 15, 225-253Jitariu A, Cîmpean A, Ribatti D, Raica M. Triple negative breast cancer: the kiss of death. Oncotarget. 2017; 8(28): 46652-46662Medina M, Oza G, Sharma A, Arriaga L, Hernández J, Rotello V, et al. Triple negative breast cancer: A review of conventional and advanced therapeutic strategies. Int J Environ Res Public Health. 2020; 17(6):1–32Berry D, Cirrincione C, Henderson I, Citron M, Budman D, Goldstein L, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006; 295(14):1658-67Jones S, Savin M, Holmes F, O'Shaughnessy J, Blum J, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006; 24(34): 5381-7Sikov W, Berry D, Perou C, Singh B, Cirrincione C, Tolaney S, et el. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015; 33(1): 13-21Vaz-Luis I, Ottesen R, Hughes M, Mamet R, Burstein H, Edge S, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014; 32(20):2142-50Tutt A, Garber J, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021; 384(25): 2394- 2405Tung N, Zakalik D, Somerfield M. Hereditary Breast Cancer Guideline Expert Panel. Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update. J Clin Oncol. 2021; 39(26): 2959-2961Abdel-Rahman O. Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. Breast Cancer Res Treat 2018; 168: pp. 269- 275Ibis K, Ozkurt S, Kucucuk S, Yavuz E, Saip P. Comparison of pathological prognostic stage and anatomic stage groups according to the updated version of the American Joint Committee on Cancer (AJCC) breast cancer staging 8th edition. Med Sci Monit 2018; 24: pp. 3637-3643Liedtke C, Mazouni C, Hess K, André F, Tordai A, Mejia J, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008; 68(9): 3108-14Lin N, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012; 118(22): 5463-72Mahtani R, Kittaneh M, Kalinsky K, Mamounas E, Badve S, Vogel C, et al. Advances in therapeutic approaches for triple-negative breast cancer. Clin Breast Cancer. 2021;21(5):383–90Sung H, Wiese D, Jatoi I, Jemal A. State variation in racial and ethnic disparities in incidence of triple-negative breast cancer among US women. JAMA Oncol. 2023;9(5):700–4Downs-Canner S, Mittendorf EA. Selecting triple negative breast cancer patients for immunotherapy. Surg Oncol Clin N Am 2023; 32-4Yoon J, Knapp G, Quan ML, Bouchard-Fortier A. Cancer-specific outcomes in the elderly with triple-negative breast cancer: A systematic review. Curr Oncol. 2021;28(4):2337–45Zouré AA, Bambara AH, Sawadogo AY, Ouattara AK, Ouédraogo M, Traoré SS, et al. Multiparity and breast cancer risk factor among women in Burkina Faso. Asian Pac J Cancer Prev. 2016;17(12):5095–9Pavese F, Capoluongo ED, Muratore M, Minucci A, Santonocito C, Fuso P, et al. BRCA mutation status in triple-negative breast cancer patients treated with Neoadjuvant chemotherapy: A pivotal role for treatment decision-making. Cancers (Basel). 2022;14(19):4571Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020;10(1):225Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72Brawley OW, Lansey DG. Disparities in breast cancer outcomes and how to resolve them. Hematol Oncol Clin North Am. 2023;37(1):1–15http://purl.org/coar/access_right/c_abf2THUMBNAILMESTRE.pdf.jpgMESTRE.pdf.jpgPortadaimage/jpeg91656http://repository.unilibre.edu.co/bitstream/10901/28475/5/MESTRE.pdf.jpg640da69712fdc788568d4cbda03807f5MD55FORMULARIO AUTORIZACION.pdf.jpgFORMULARIO AUTORIZACION.pdf.jpgIM Thumbnailimage/jpeg28984http://repository.unilibre.edu.co/bitstream/10901/28475/6/FORMULARIO%20AUTORIZACION.pdf.jpgf887b39f7c8d5f8f7424ff06e41f668bMD56LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://repository.unilibre.edu.co/bitstream/10901/28475/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53ORIGINALMESTRE.pdfMESTRE.pdfapplication/pdf570636http://repository.unilibre.edu.co/bitstream/10901/28475/1/MESTRE.pdf673af96ac6e52f6c0605ea69e4d9217aMD51FORMULARIO AUTORIZACION.pdfFORMULARIO AUTORIZACION.pdfapplication/pdf304058http://repository.unilibre.edu.co/bitstream/10901/28475/2/FORMULARIO%20AUTORIZACION.pdf60285f140c8ae9d010df68c37bbc1f48MD5210901/28475oai:repository.unilibre.edu.co:10901/284752024-09-16 06:01:12.193Repositorio Institucional Unilibrerepositorio@unilibrebog.edu.coTk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo=

Publicaciones similares